Having a Healthy Baby with Genetic Disorders: Hong Kong's Third-Generation IVF PGT Technology Explained

Opening: Real Consultation Scenario

"Doctor, both my partner and I are carriers of Spinal Muscular Atrophy (SMA). With natural pregnancy, there is a 25% chance each time of having a baby with the disease. Can Hong Kong's third-generation IVF technology completely help us screen out the disease-causing embryos?"
This is a consultation scenario I often encounter in my work. Behind such questions lies the urgent hope of countless families carrying genetic disorders to have healthy offspring.

Module A: Direct Answer to the Question

Can PGT Technology Solve Genetic Disorder Problems?

PGT (Preimplantation Genetic Testing) technology can indeed screen embryos for genetic disorders, but the statement "completely screen out disease-causing embryos" needs to be understood on two levels. For most monogenic diseases—such as SMA, thalassemia, hemophilia, hereditary deafness, etc.—PGT-M (Monogenic Disease Testing) can accurately identify embryos carrying the disease-causing gene by constructing haplotypes or directly detecting pathogenic sites, thereby selecting healthy embryos for transfer.

However, the technology has certain limitations. Clinical data shows that the diagnostic accuracy of PGT-M for monogenic diseases is usually between 98% and 99%, not 100%. Testing errors mainly arise from the following three situations:

• Mosaic Embryos: Embryos contain both normal and abnormal cell lines, and the cells biopsied may not represent the true genetic status of the entire embryo.
• Allele Dropout (ADO): During PCR amplification, one allele fails to amplify, leading to a misdiagnosis as homozygous.
• De Novo Mutations: New pathogenic mutations appear in the embryo during development that are not carried by either parent.

Therefore, when is it suitable? PGT is an effective prevention and control method when there is a clear genetic cause, the pathogenic site has been identified, and both partners have good reproductive function to obtain a sufficient number of embryos (usually recommended 5-8 or more blastocysts). When is it unsuitable? When the genetic cause is unclear, ovarian reserve is severely insufficient (AMH < 0.5 ng/mL), or advanced age (≥42 years) leads to very few embryos, the benefits of PGT significantly decrease, and there may even be no healthy embryos available for transfer.

Module C: The Doctor's Perspective

How Do Doctors Assess PGT Suitability?

The field of reproductive medicine takes a cautious approach to the clinical application of PGT. Doctors will focus on evaluating the following five dimensions:

• Is the genetic cause clear and detectable?: The pathogenic gene and site must be clearly identified in the proband (affected family member) or both partners. Lack of a proband sample significantly increases testing difficulty and misdiagnosis risk.
• Is reproductive function sufficient to obtain enough embryos?: It is recommended to obtain 5-8 or more blastocysts for testing to increase the probability of screening for healthy embryos. Patients with low ovarian reserve or advanced age need full communication of expectations.
• Age and Ovarian Reserve Function: Patients of advanced age (≥40 years) or with poor ovarian response (AFC < 5) may find it difficult to obtain enough embryos, and clinical pregnancy rates will also decrease.
• Psychological and Financial Capacity: PGT cycles are costly, and there is a risk of having no healthy embryos available for transfer. Patients need to be prepared accordingly.
• Ethical and Legal Compliance: The Hong Kong Human Reproductive Technology Authority (HKHRTA) requires each PGT case to be submitted for ethics committee approval, ensuring the technology's application meets ethical standards.

Module E: Differences Between Countries

Differences in Clinical Application of PGT between Hong Kong and Mainland China

There are significant differences in the clinical application of PGT between Hong Kong, Mainland China, and overseas. Understanding these differences helps patients make choices more suitable to their own circumstances.

Hong Kong's medical regulatory system is closer to international standards, with a comprehensive laboratory quality control (QC) system, and it allows PGT testing for some mitochondrial diseases, an area not yet widely practiced in Mainland China. However, patients also need to consider the time cost of cross-border medical care, accommodation arrangements, and medical visas (if required).

Module G: Easily Overlooked Details

Easily Overlooked Details in PGT Testing

In the clinical application of PGT, several details are easily overlooked by patients and even some clinical staff. These details directly affect the accuracy and final outcome of the test.

• Importance of Proband Sample: When constructing a PGT-M testing plan, the ideal situation is to obtain a DNA sample from the proband (affected family member). Without a proband sample, detection must be inferred indirectly through haplotype analysis or linkage analysis, increasing testing difficulty and misdiagnosis risk.
• Number and Location of Cells in Blastocyst Biopsy: Biopsy takes 5-10 trophectoderm cells, which could theoretically damage the embryo. However, clinical data shows that the survival rate after blastocyst biopsy exceeds 95%, and there is no significant difference in clinical pregnancy rates compared to non-biopsied embryos. The safety is ensured by having the biopsy performed by an experienced embryologist.
• Decision Dilemma for Mosaic Embryos: About 5% to 10% of blastocysts exhibit mosaicism. For mosaic embryos, test results may not accurately reflect the overall genetic status of the embryo. The decision to transfer a mosaic embryo requires joint decision-making by genetic counselors, clinicians, and patients, considering the mosaic ratio, the genes and chromosomal regions involved.
• Prenatal Diagnosis Still Needed After PGT: PGT has a misdiagnosis rate of about 1% to 2%. It is strongly recommended to confirm the fetal genetic status after pregnancy through chorionic villus sampling (at 11-14 weeks of gestation) or amniocentesis (at 16-22 weeks of gestation). This is an indispensable safety step in the PGT process.
• Unpredictability of De Novo Mutations: PGT can only detect known pathogenic sites and cannot identify new pathogenic mutations that appear in the embryo during development. For cases with a family history of genetic disorders where neither parent carries the pathogenic gene (i.e., the proband's condition is caused by a de novo mutation), the PGT testing strategy needs to be designed separately.

Module I: Actual Process

Actual Process for PGT Medical Care in Hong Kong

From the initial consultation to completing the transfer, the complete PGT process in Hong Kong usually takes 2 to 3 months, depending on the complexity of the genetic testing plan and the patient's reproductive function. The following is the standard process:

1. Genetic Counseling and Evaluation (1st visit to Hong Kong): Bring genetic disease diagnosis reports and proband samples (if available) for genetic counseling to assess suitability for PGT and develop a testing plan.
2. Genetic Testing and Site Verification: Collect blood samples from both partners. Complete pathogenic site verification and detection probe design in a certified laboratory. This takes about 3-4 weeks. This step can be done by collecting specimens in Mainland China and sending them to Hong Kong.
3. Reproductive Function Assessment: Female partner tests AMH, FSH, LH, and antral follicle count (AFC). Male partner undergoes semen analysis. Results determine the ovulation induction protocol.
4. Sign Informed Consent: After fully understanding the expectations, risks, limitations, and costs of PGT, sign the consent form and obtain ethics approval.
5. Ovulation Induction and Egg Retrieval: Use an individualized ovulation induction protocol (commonly antagonist or long protocol). Perform egg retrieval surgery after follicles mature. The entire process takes about 10-14 days.
6. In Vitro Fertilization and Blastocyst Culture: Use ICSI (Intracytoplasmic Sperm Injection) for fertilization to avoid sperm source contamination affecting testing. Culture to the blastocyst stage (day 5-6).
7. Embryo Biopsy and Genetic Testing: Perform trophectoderm cell biopsy on blastocysts and send for genetic testing. Embryos are cryopreserved by vitrification during testing.
8. Embryo Transfer: Select one healthy blastocyst for thawed embryo transfer based on test results. The transfer procedure takes about 15 minutes and requires no anesthesia.
9. Pregnancy Confirmation and Prenatal Diagnosis: Test blood for HCG 12-14 days after transfer to confirm pregnancy. Perform chorionic villus sampling at 11-14 weeks or amniocentesis at 16-22 weeks to verify genetic results.

Module K: Factors Affecting Cost

PGT Cost Composition and Influencing Factors

The cost of PGT in Hong Kong is not fixed but is determined by multiple variables. The table below lists the main cost items and influencing factors:

Overall estimate: The total cost for one complete PGT-M cycle (including testing 5-8 embryos) is usually between HKD 150,000 and 250,000. Costs will increase if more embryos are tested or multiple ovulation induction cycles are needed.

Module M: Case Scenario Analysis

Analysis of Typical Genetic Disease Cases

Case 1: Couple Both Carriers of β-Thalassemia

A couple, both carriers of β-thalassemia, have a 25% chance with natural pregnancy of having a child with severe thalassemia (requiring lifelong blood transfusions or bone marrow transplant). Through PGT-M testing, 9 blastocysts were obtained. Among them, 2 were completely normal, 4 were carriers (like the parents), and 3 had severe thalassemia. One completely normal embryo was selected for transfer, resulting in a successful pregnancy. Prenatal diagnosis confirmed the fetus had a completely normal genotype, and a healthy baby was delivered at full term.

Case 2: Hemophilia Carrier (X-linked Recessive Inheritance)

A woman carries the pathogenic gene for Hemophilia A (F8 gene mutation), and her father is a hemophilia patient. She wishes to avoid having male offspring with the disease. Through PGT-M testing, female embryos (carriers or completely non-carriers of the pathogenic gene) were selected for transfer. Ultimately, one female carrier embryo (carriers usually have no clinical symptoms) was transferred, resulting in a successful pregnancy and the birth of a healthy baby girl.

Case 3: Recurrent Miscarriage Due to Chromosomal Balanced Translocation

A couple experienced 3 recurrent miscarriages due to a balanced chromosomal translocation in the male partner (46,XY,t(2;5)(q21;q23)). Through PGT-SR (Structural Rearrangement Testing), embryos with normal chromosomal structure were selected. A total of 6 blastocysts were tested. Among them, 2 had normal chromosomal structure, 3 were balanced translocation carriers, and 1 had an unbalanced translocation. One normal embryo was transferred, resulting in a successful pregnancy. Prenatal diagnosis confirmed a normal fetal karyotype, and the pregnancy continued to full term.

Module Q: Frequently Asked Questions

Answers to Frequently Asked Questions

Q1: How long does PGT testing take?

From genetic counseling to obtaining test results, it usually takes 2 to 3 months. Ovulation induction and egg retrieval take about 2 weeks, embryo culture to blastocyst takes 5-6 days, genetic testing takes about 3-4 weeks, and frozen embryo transfer takes about 1 month. If testing probes need to be redesigned or samples supplemented, the time will be extended accordingly.

Q2: How accurate is PGT testing?

The accuracy of PGT-M for monogenic diseases is about 98% to 99%, and the accuracy of PGT-SR for chromosomal structural abnormalities is about 95% to 98%. Testing errors mainly arise from mosaicism, allele dropout (ADO), and de novo mutations. Choosing an experienced laboratory with a robust quality control system can minimize errors.

Q3: Does PGT testing damage the embryo?

Blastocyst biopsy takes 5-10 trophectoderm cells, which has minimal impact on the inner cell mass (the part that develops into the fetus). Clinical data shows that the survival rate of blastocysts after biopsy exceeds 95%, and there is no significant difference in clinical pregnancy rates compared to non-biopsied embryos. It is crucial that the biopsy is performed by an experienced embryologist.

Q4: Is prenatal diagnosis still needed after PGT testing?

Prenatal diagnosis is strongly recommended. PGT testing has a misdiagnosis rate of about 1% to 2%. Prenatal diagnosis can ultimately confirm the fetal genetic status. It is recommended to verify through chorionic villus sampling (at 11-14 weeks of gestation) or amniocentesis (at 16-22 weeks of gestation). This is the final line of defense to ensure diagnostic accuracy.

Q5: What are the advantages of PGT technology in Hong Kong compared to Mainland China?

The main advantages of Hong Kong are: ① Transparent regulatory system with a clear ethics approval process; ② Laboratory quality control standards aligned with international standards, and test results are recognized by most reproductive centers globally; ③ Allows PGT testing for some mitochondrial diseases; ④ Language communication barriers are relatively low, with some institutions offering Mandarin services. However, disadvantages include higher costs and the need for cross-border medical care, requiring consideration of both time and financial costs.

Ending: Risk Reminder

This article is compiled based on clinical consensus in assisted reproductive medicine and public information from the Hong Kong Human Reproductive Technology Authority. The content is for informational reference only and does not constitute medical advice. Please consult a licensed physician for specific diagnosis and treatment plans.